4.8 Article

Inhibition of CRISPR-Cas9 with Bacteriophage Proteins

期刊

CELL
卷 168, 期 1-2, 页码 150-+

出版社

CELL PRESS
DOI: 10.1016/j.cell.2016.12.009

关键词

-

资金

  1. University of California, San Francisco Program for Breakthrough in Biomedical Research
  2. Sandler Foundation
  3. NIH Office of the Director Early Independence Award [DP5-OD021344]
  4. National Science Foundation [1144247]
  5. Carol Gross' lab by Mira [R35GM118061]
  6. amFAR Mathilde Krim Fellowship [109504-61-RKRL]
  7. NIH Human Immunology Project Consortium Infrastructure Pilot [U19 AI118610]
  8. NIH [P30 AI027763]
  9. NIH HIV Accessory & Regulatory Complexes (HARC) Center [P50 GM082250]

向作者/读者索取更多资源

Bacterial CRISPR-Cas systems utilize sequencespecific RNA-guided nucleases to defend against bacteriophage infection. As a countermeasure, numerous phages are known that produce proteins to block the function of class 1 CRISPR-Cas systems. However, currently no proteins are known to inhibit the widely used class 2 CRISPR-Cas9 system. To find these inhibitors, we searched cas9-containing bacterial genomes for the co-existence of a CRISPR spacer and its target, a potential indicator for CRISPR inhibition. This analysis led to the discovery of four unique type II-A CRISPR-Cas9 inhibitor proteins encoded by Listeria monocytogenes prophages. More than half of L. monocytogenes strains with cas9 contain at least one prophage-encoded inhibitor, suggesting widespread CRISPR-Cas9 inactivation. Two of these inhibitors also blocked the widely used Streptococcus pyogenes Cas9 when assayed in Escherichia coli and human cells. These natural Cas9-specific anti-CRISPRs'' present tools that can be used to regulate the genome engineering activities of CRISPR-Cas9.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据